Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sawai Pharmaceutical Co., Ltd.

https://www.sawai.co.jp/en/

Latest From Sawai Pharmaceutical Co., Ltd.

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

Coronavirus COVID-19 Generic Drugs

Sawai Claims A First With Japanese Pregabalin Launch

Sawai has launched what it says is Japan’s first generic version of Pfizer’s Lyrica pregabalin brand, with other Japanese generics firms waiting in the wings.

Launches Generic Drugs

Sawai Sets Out US Recalibration

Sawai Pharmaceutical has major plans for its US business that include consolidating its manufacturing operations at a single site and bolstering its pipeline and portfolio, Sawai president Kenzo Sawai tells Generics Bulletin in an exclusive interview.

Strategy United States

Sawai Draws On Its Strengths Despite Japanese Pressures

In the face of both local and global pressures, Japan’s Sawai Pharmaceutical is holding steady by relying on its core strengths, company president Kenzo Sawai tells Generics Bulletin in the first part of an exclusive two-part interview.

Strategy Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Cambridge Biotechnology Ltd (CBT)
    • Minster Pharmaceuticals
    • Proximagen Group
    • Upsher-Smith Laboratories Inc.
    • Medisa Shinyaku Inc. and Kaken Shoyaku Inc.
UsernamePublicRestriction

Register